Bank of America
AARD

Bank of America’s Aardvark Therapeutics AARD Stock Holding History

Bank of America’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.3K Sell
11,486
-19,174
-63% -$199K ﹤0.01% 5618
2025
Q4 		$402K Buy
30,660
+6,730
+28% +$84K ﹤0.01% 5029
2025
Q3 		$318K Buy
23,930
+15,941
+200% +$180K ﹤0.01% 6049
2025
Q2 		$108K Buy
7,989
+3,369
+73% +$34.7K ﹤0.01% 6490
2025
Q1 		$34.7K Buy
+4,620
New +$51.9K ﹤0.01% 6834

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America's AARD Position: Q1 2026 in Review

Bank of America reduced its Aardvark Therapeutics (AARD) stake by 63% in Q1 2026, selling an estimated $199K and leaving 11,486 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5618.

Bank of America first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $402K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Bank of America held 11,486 shares of Aardvark Therapeutics worth $43.3K as of Q1 2026.
  • Bank of America sold 19,174 Aardvark Therapeutics shares in Q1 2026, an estimated $199K.
  • Aardvark Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5618 holding.
  • Bank of America first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Bank of America's Aardvark Therapeutics position peaked at $402K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.